World Health Organization Issues Warning Over Severe Lack of Obesity Jabs
Fewer than 10% of people that would benefit from GLP-1 drugs like Wegovy have access to them, caution the World Health Organization as it publishes its inaugural advice on the drugs.
With over a billion people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
Per forecasts, more than two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be addressed with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can assist patients in reducing substantial body mass, notes the body.
GLP-1 Therapy Scarcity
Even under the present best projected scenario, the manufacturing of such drugs might only reach about 100 million people – under 10% of those who need them, per the health organization.
The recommendation encourages nations and manufacturers to widen availability, through strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Drugs Function
These medications replicate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so users eat less.
People commonly begin shedding pounds within a few weeks of commencing the regular doses.
Evidence points to people may put most of the weight back on within a year of discontinuing the drug, because their typical hunger come back.
Being overweight or obese elevates your chance for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts individuals in every country and was associated with millions of deaths worldwide in 2024, per the health agency.